General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL, previously untreated in adult patients. (in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP))
Last updated January 10, 2025
Status:
Concluded without agreement
Manufacturer:
Incyte Biosciences Canada Corporation
Indication:
Unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement and a ECOG performance status of 0 to 2, Previously treated, in adults
Last updated December 20, 2024
Status:
Concluded with an LOI
Manufacturer:
Argenx Canada Inc.
Indication:
Generalized myasthenia gravis (gMG)
Last updated December 13, 2024
Pluvicto (lutetium vipivotide tetraxetan)
Status:
Concluded with an LOI
Manufacturer:
Advanced Accelerator Applications
Indication:
Prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have received at least one androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy.
Last updated December 12, 2024
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Rheumatoid Arthritis
Last updated November 26, 2024
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Crohn's disease
Last updated November 26, 2024
Status:
Concluded with an LOI
Manufacturer:
Celltrion Healthcare Canada Ltd.
Indication:
Ulcerative Colitis
Last updated November 26, 2024
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Multiple Indications
Last updated November 19, 2024
Status:
Concluded with an LOI
Manufacturer:
Alexion Pharma GmbH
Indication:
Neurofibromatosis type 1 in pediatric patients aged 2 years and above, who have symptomatic, inoperable plexiform neurofibromas
Last updated November 19, 2024
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
In combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Last updated November 15, 2024